Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 22 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Antiviraux à action directe: interaction avec les antivitamine K. Prescrire 2017;37:262. [Ref.ID 101533]
3. Cita con resumen
Anónimo. Daclatasvir. Prescrire 2015;35:738-9. [Ref.ID 99846]
4. Cita con resumen
Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]
5. Cita con resumen
Gray AL, Wirtz VJ, 't Hoen EFM, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386:1601-3. [Ref.ID 99632]
6. Cita con resumen
Anónimo. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. U.S. Food and Drug Administration 2015:22 de octubre. [Ref.ID 99573]
7. Cita con resumen
Wilensky G. A new focus on prescription drug spending. JAMA 2015;314:440-1. [Ref.ID 99400]
8. Cita con resumen
Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska F, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502-9. [Ref.ID 99305]
9. Cita con resumen
Anónimo. A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther 2015;57:15-7. [Ref.ID 98854]
10. Cita con resumen
Herman AO. State Medicaid programs seek discounts on pricey hepatitis C drugs. Physician's First Watch 2015:2 de febrero. [Ref.ID 98749]
11. Cita con resumen
Anónimo. AbbVie’s HCV treatment cleared in Europe. DIA Daily 2015:20 de enero. [Ref.ID 98718]
12. Cita con resumen
Anónimo. FDA approves Viekira Pak to treat hepatitis C. U.S. Food and Drug Administration 2014:19 de diciembre. [Ref.ID 98390]
13. Cita con resumen
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Fisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R, for the VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001. [Ref.ID 97630]
14. Cita con resumen
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, Podsadecki T, Reddy KR. ABT-450/r - Ombitasvir and dasabuvir with or for HCV. N Engl J Med 2014;370:1983-92. [Ref.ID 97629]
15. Cita con resumen
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r - Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82. [Ref.ID 97628]
16.Tiene citas relacionadas Cita con resumen
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gómez M, Zarski J-P, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, for the ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98. [Ref.ID 97605]
17.Tiene citas relacionadas Cita con resumen
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, for the ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88. [Ref.ID 97604]
18. Cita con resumen
Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014;370:1869-71. [Ref.ID 97602]
19.Tiene citas relacionadas Cita con resumen
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14. [Ref.ID 97490]
20.Tiene citas relacionadas Cita con resumen
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603. [Ref.ID 97489]
Seleccionar todas
 
 1 a 20 de 22 siguiente >>